reduce basal insulin dose when starting glp-1 receptor agonist Adding a was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation GLP-1 receptor agonists and beyond.

Full escalation schedules, unit conversions, weight loss data, and switching protocols.

Some Medicare patients will be able to access GLP-1 medication for weight loss for the first time starting July 1, paying a $50 monthly copay through a new program designed to make the drugs more...

CMS GLP-1 Bridge Program: Medicare Part D coverage for weight-loss GLP-1 drugs starting July 1, 2026, including eligibility, covered medications, prior authorization, and copay rules.

Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide

Overall, the EASD-ADA consensus provides a dynamic framework that supports a multifaceted, patient-centric approach to type 2 diabetes care, aiming to reduce complications, improve quality of life, and promote long-term health outcomes

Here, the authors review the physiological roles of GLP-1, the potential renoprotective mechanisms of incretin-based therapies and the available renal outcome data from clinical trials.